IDEAYA Announces Positive Interim Phase 2 Data for Darovaser

IDEAYA Announces Positive Interim Phase 2 Data for Darovasertib and Crizotinib Combination and Successful FDA Type C Meeting on Registrational Trial Design for Accelerated Approval in First-Line Metastatic Uveal Melanoma

Confirmed overall response rate of 45%, disease control rate of 90% and median PFS of ~7 months in 20 evaluable First-Line MUM patientsBased on FDA meeting, initiating Phase 2/3 registrational... | April 23, 2023

Related Keywords

Russia , Monash , South Australia , Australia , Ukraine , Sydney , New South Wales , Melbourne , Victoria , Neoadjuvant Po , Meredith Mckean , Anthony Joshua , Mark Shackleton , Darrin Beaupre , Yujiros Hata , Werner Helicase , While The Company , St Vincent Hospital Garvan Medical Research Institute , Pfizer , Nasdaq , Vincent Hospital Sydney , Head Of The Department Medical Oncology , Exchange Commission , Novartis , Biosciences Inc , Company Annual Report On Form , Kinghorn Cancer Centre , Skin Cancer Research , Sarah Cannon Research , Chief Medical Officer , Data Update , Crizotinib Combination , Overall Response Rate , Disease Control Rate , Progression Free Survival , Typec Meeting Supports Initiation , Potential Registrational , Adjuvant Primary , Medical Oncology , Garvan Medical Research Institute , Hospital Sydney Limited , Patient Population , Eastern Time , Sarah Cannon Research Institute , Skin Cancer Trials , Chief Executive Officer , Investor Relations , Private Securities Litigation Reform Act , Annual Report , Vice President , Chief Financial Officer , Ideaya Biosciences , Nc Stock Exchange , News , Information , Press Release , Onfirmed , Verall , Response , Gate , F , Disease , Control , End , Comedian , Ifs , Months , N , 0 , Valuable , Um , Atientsbased , Fda , Initiating , Hase Idya Us45166a1025 ,